Effects of norfluoxetine on the action potential and transmembrane ion currents in canine ventricular cardiomyocytes.
Norfluoxetine is the most important active metabolite of the widely used antidepressant compound fluoxetine. Although the cellular electrophysiological actions of fluoxetine are well characterized in cardiac cells, little is known about the effects of its metabolite. In this study, therefore, the effects of norfluoxetine on action potential (AP) configuration and transmembrane ion currents were studied in isolated canine cardiomyocytes using the whole cell configuration of patch clamp techniques. Micromolar concentrations of norfluoxetine (1-10 microM) modified AP configuration: amplitude and duration of the AP and maximum velocity of depolarization were decreased in addition to depression of the plateau and elimination of the incisura of AP. Voltage clamp experiments revealed a concentration-dependent suppression of both L-type Ca(2+) current, I(Ca) (EC(50)=1.13+/-0.08 microM) and transient outward K(+) current, I(to) (EC(50)=1.19+/-0.17 microM) having Hill coefficients close to unity. The midpoint potential of the steady-state inactivation of I(Ca) was shifted from -20.9+/-0.75 mV to -27.7+/-1.35 mV by 3 microM norfluoxetine ( P<0.05, n=7). No such shift in the steady-state inactivation curve was observed in the case of I(to). Similarly, norfluoxetine caused no change in the steady-state current-voltage relationship of the membrane or in the density of the inward rectifier K(+) current, I(K1). All these effects of norfluoxetine developed rapidly and were fully reversible. Comparing present results with those obtained previously with fluoxetine, it can be concluded that norfluoxetine displays stronger suppression of cardiac ion channels than fluoxetine. Consequently, the majority of the cardiac side effects observed during fluoxetine treatment are likely to be attributed to its metabolite norfluoxetine.
Magyar
János
J
Department of Physiology, University Medical School of Debrecen, PO Box 22, 4012, Debrecen, Hungary.
Szentandrássy
Norbert
N
Bányász
Tamás
T
Kecskeméti
Valéria
V
Nánási
Péter P
PP
D000200:Action Potentials / Q000187:drug effects*; D000818:Animals; D004285:Dogs; D005473:Fluoxetine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D007473:Ion Channels / Q000187:drug effects; D008564:Membrane Potentials / Q000187:drug effects; D032383:Myocytes, Cardiac / Q000187:drug effects*; D018408:Patch-Clamp Techniques; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology
D005473:Fluoxetine; D007473:Ion Channels; D017367:Selective Serotonin Reuptake Inhibitors; C036139:norfluoxetine